US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MetaVia Inc

0.7620

+0.00100.13%

Post-market: 0.7501-0.0119-1.56%19:48 EDT

Volume:77.70K

Turnover:58.53K

Market Cap:7.68M

PE:-0.21

High:0.7667

Open:0.7600

Low:0.7440

Close:0.7610

Loading ...

Overview Company News Filings

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy

MetaVia Inc. Reports Progress in Cardiometabolic Drug Development

MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY

Press Release: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

HC Wainwright Initiates MetaVia at Buy With $12 Price Target

MT Newswires Live

U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

Zacks Small Cap Research

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MetaVia Reports Positive Phase 2a Results for DA-1241 in Presumed MASH Patients

MT Newswires Live

BRIEF-Metavia Announces Positive Top-Line Results From Its Phase 2A Clinical Trial Of Da-1241 In Patients With Presumed MASH

Metavia Inc - Da-1241 Shows Significant Reduction in Alt Levels at Weeks 4 and 8

THOMSON REUTERS

Metavia Inc - Expects End of Phase 2 Meeting With FDA in First Half of 2025

THOMSON REUTERS

Metavia Inc - Da-1241 Very Well Tolerated With No Drug-Related Serious Adverse Events

THOMSON REUTERS

Metavia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of Da-1241 in Patients With Presumed Mash

THOMSON REUTERS

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

Zacks Small Cap Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MTVA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":0.762,"timestamp":1746129600000,"preClose":0.761,"halted":0,"volume":77697,"hourTrading":{"tag":"盘后","latestPrice":0.7501,"preClose":0.762,"latestTime":"19:48 EDT","volume":25291,"amount":19214.3946,"timestamp":1746143299722},"delay":0,"floatShares":3766600,"shares":10084900,"eps":-3.56,"marketStatus":"Closed","change":0.001,"latestTime":"05-01 16:00:00 EDT","open":0.76,"high":0.7667,"low":0.744,"amount":58533.081568199996,"amplitude":0.029829,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.56,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746172800000},"marketStatusCode":5,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.761,"preHourTrading":{"tag":"盘前","latestPrice":0.7751,"preClose":0.761,"latestTime":"09:15 EDT","volume":834,"amount":647.36748,"timestamp":1746105314161},"postHourTrading":{"tag":"盘后","latestPrice":0.7501,"preClose":0.762,"latestTime":"19:48 EDT","volume":25291,"amount":19214.3946,"timestamp":1746143299722},"volumeRatio":0.647259},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":3766600,"roa":"-92.24%","roe":"-224.18%","lyrEps":-3.556986,"volumeRatio":0.647259,"shares":10084900,"dividePrice":0,"high":0.7667,"amplitude":0.029829,"preClose":0.761,"low":0.744,"week52Low":0.647,"pbRate":"0.97","week52High":5.3,"institutionHeld":0,"latestPrice":0.762,"eps":-3.56,"divideRate":0,"volume":77697,"delay":0,"ttmEps":-3.56,"open":0.76,"prevYearClose":2.03,"prevWeekClose":0.8226,"prevMonthClose":0.761,"prevQuarterClose":1.54,"fiveDayClose":0.85,"twentyDayClose":1.54,"sixtyDayClose":1.74},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521073767","title":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521073767","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521073767?lang=en_us&edition=fundamental","pubTime":"2025-03-24 15:55","pubTimestamp":1742802941,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty EnergyMarch 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed compani","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL3N3Q70IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRT","FDX","LU1064131342.USD","BRZE","IONS","IE00BFTCPJ56.SGD","LU1366333091.USD","BBIO","LU2456880835.USD","IE00B0JY6N72.USD","LU0719512351.SGD","LU0738911758.USD","LU0056508442.USD","VRTX","LU1804176565.USD","LU2361045086.USD","DRI","LU0557290698.USD","LU1951200564.SGD","LU0792757196.USD","LU1201861249.SGD","LU1720051017.SGD","NOV","LU1267930227.SGD","HUBS","LU0417517546.SGD","LU2236285917.USD","LU1429558221.USD","LU2756315318.SGD","BECN","CRM","LU0642271901.SGD","LEN","IE00B4R5TH58.HKD","LU0256863811.USD","LU2458330243.SGD","RXST","IE00B19Z3B42.SGD","ALHC","SLB","LU2264538146.SGD","IE00B5949003.HKD","LU0251142724.SGD","BK4607","LU2362541513.USD","LU0238689110.USD","MTVA","ALNY","LU2362540622.SGD"],"gpt_icon":1},{"id":"2521929661","title":"MetaVia Inc. Reports Progress in Cardiometabolic Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2521929661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521929661?lang=en_us&edition=fundamental","pubTime":"2025-03-22 11:53","pubTimestamp":1742615610,"startTime":"0","endTime":"0","summary":"Neurobo Pharmaceuticals, Inc. ( ($MTVA) ) has released its Q4 earnings. Here is a breakdown of the information Neurobo Pharmaceuticals, Inc. presen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metavia-inc-reports-progress-in-cardiometabolic-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metavia-inc-reports-progress-in-cardiometabolic-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2065732104.USD","PRGS","BK4097","MTVA"],"gpt_icon":0},{"id":"2521815252","title":"MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521815252","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521815252?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:12","pubTimestamp":1742562720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 09:12 ET (13:12 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2520945338","title":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2520945338","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520945338?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:50","pubTimestamp":1742471448,"startTime":"0","endTime":"0","summary":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44414209/metavia-2024-eps-3-56-down-from-2-46-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2520458331","title":"Press Release: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458331?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:31","pubTimestamp":1742470260,"startTime":"0","endTime":"0","summary":"Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025. Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect. $16.0 Million in Cash at End of Fourth Quarter Expected to Fund the Company Into the Third Quarter of 2025. CAMBRIDGE, Mass., March 20, 2025 /PRNewswire/ -- MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update.Mr. Kim continued, \"In December, we reported positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . DA-1241 met the primary endpoint, achieving a reduction in alanine transaminase","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","MTVA","BK4202","GGT","OXM","ALT","BK4139","BK4599"],"gpt_icon":0},{"id":"2503581014","title":"Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503581014","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503581014?lang=en_us&edition=fundamental","pubTime":"2025-01-13 17:00","pubTimestamp":1736758800,"startTime":"0","endTime":"0","summary":"Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model that comes from our 11 experienced analysts’ expertise and due diligence. Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based products, and oil and gas production among other industries.The last year has been one fraught with risks, critical elections around the globe and multiple ongoing military conflicts among other material events. Despite this, index performance as measured by the S&P was positive in 2024, with large caps outperforming mid-caps and mid-caps surpassing small caps. Much of the strong performance was driven by tech stocks and the Magnificent Seven while other areas lagged.Ligand Pharmaceuticals  is a royalty aggregator which has a large opportunity set of biopharma names where it can deploy its capital f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-small-cap-research-2024-090000334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","BK4139","USJW.SI","NVIW.SI","BK4166","BK4579","MNQmain","VIOT",".IXIC","TSYW.SI","LU1559883803.SGD","MTVA","BK4007","CPSS","QLD","USAW.SI","TWI","TELO","BK4191","PSQ","LU0566484027.USD","QID","SQQQ","BK4152","LGND","TQQQ"],"gpt_icon":1},{"id":"2502286335","title":"MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2502286335","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502286335?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:05","pubTimestamp":1736514300,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ --MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss the previously announced positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-hold-advisory-committee-meeting-130500948.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-hold-advisory-committee-meeting-130500948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MTVA","OXM","BK4139","BK4202"],"gpt_icon":0},{"id":"2495654684","title":"HC Wainwright Initiates MetaVia at Buy With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2495654684","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495654684?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:21","pubTimestamp":1735561274,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates MetaVia at Buy With $12 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTVA"],"gpt_icon":0},{"id":"2495354814","title":"U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2495354814","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495354814?lang=en_us&edition=fundamental","pubTime":"2024-12-30 19:40","pubTimestamp":1735558819,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent Dec 30  - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.  HIGHLIGHTS    * Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating * Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating * BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3* Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97 * Emerg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nL4N3NV0FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2506951958.HKD","LU1023059063.AUD","BSX","EBS","LU1061106388.HKD","BK4551","BK4539","BK4587","BK4082","LU0267386448.USD","LU1153585028.USD","BK4139","LU0187121727.USD","LU0823416689.USD","BK4581","LU2491049909.HKD","LU2324357040.USD","MTVA","LU0353189680.USD","LU0122379950.USD","BBAI","LU0238689110.USD","LU2265009873.SGD","NUVL","LU1804176565.USD","LU1989772923.USD","LU2362540622.SGD","LU2491050154.USD","LU0011850046.USD","LU2506952097.USD","LU0823417737.USD","LU0345769631.USD","LU2491050071.SGD","PODD","LU0048584097.USD","IE00BJT1NW94.SGD","LU0882574055.USD","BK4583","LU0950375773.USD","LU2087625088.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","LU1718418525.SGD","EXEL","ARTV","LU2362541273.HKD","LU0345769128.USD","ARQT","LU1791710582.SGD","BK4588"],"gpt_icon":1},{"id":"2495100775","title":"Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2495100775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495100775?lang=en_us&edition=fundamental","pubTime":"2024-12-30 19:31","pubTimestamp":1735558271,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MetaVia (MTVA – Research Report) and Century Therape...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-metavia-mtva-century-therapeutics-ipsc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-metavia-mtva-century-therapeutics-ipsc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA","HCSG","BK4139","BK4539","IPSC","BK4505","BK4137"],"gpt_icon":0},{"id":"2493474532","title":"MTVA:  Compelling Data for DA-1241 in Phase 2a MASH Trial…","url":"https://stock-news.laohu8.com/highlight/detail?id=2493474532","media":"Zacks Small Cap Research","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493474532?lang=en_us&edition=fundamental","pubTime":"2024-12-20 23:24","pubTimestamp":1734708240,"startTime":"0","endTime":"0","summary":"On December 18, 2024, MetaVia Inc.  announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis . The trial had two parts: in Part 1, patients were randomized in a 1:2:1 ratio into three treatment groups . In Part 2, patients were randomized in a 2:1 ratio into two treatment groups . The primary efficacy outcome was the change in alanine aminotransferase  levels from baseline at week 16.The following table gives the least square mean ALT values for each treatment group at baseline, 4 weeks, 8 weeks, and 16 weeks. DA-1241 100 mg treatment resulted in a statistically significant decrease in ALT at week 4 and week 8 and was very near statistical significance at week 16. The combination therapy of DA-1241 and sitagliptin did not show a greater effect than monotherapy DA-1241. The company has imagined that DA-1241 will ultimately be used as a combination therapy, however from this data it i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_3Rf9TBe5Z6QwMk_AfUFTA--~B/aD01NTQ7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/83fdef5b76e05a26a10e7bb8a5e4e542","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_3Rf9TBe5Z6QwMk_AfUFTA--~B/aD01NTQ7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/83fdef5b76e05a26a10e7bb8a5e4e542"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mtva-compelling-data-da-1241-152400368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MTVA","ALT","LU1878469433.USD","BK4599"],"gpt_icon":0},{"id":"2492512703","title":"MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2492512703","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492512703?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:01","pubTimestamp":1734613260,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate as a Sponsor and Exhibitor at the upcoming, 9th Annual MASH-TAG 2025 Conference. The company's participation follows the recent release of positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-participate-9th-annual-mash-130100734.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-participate-9th-annual-mash-130100734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OXM","BK4202","MTVA","BK4139"],"gpt_icon":0},{"id":"2492139429","title":"MetaVia Reports Positive Phase 2a Results for DA-1241 in Presumed MASH Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2492139429","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492139429?lang=en_us&edition=fundamental","pubTime":"2024-12-19 01:25","pubTimestamp":1734542705,"startTime":"0","endTime":"0","summary":"MetaVia  shares were down 26% in recent Wednesday trading after the company reported positive results from its two-part phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH.Part 1 of the trial is evaluating DA-1241, which is a novel g-protein-coupled receptor 119 agonist, against a placebo, while part 2 is examining the efficacy of combining DA-1241 with sitagliptin, a DPP-4 inhibitor.The trial showed that DA-1241 resulted in a statistically significant reduction in alanine transaminase levels at weeks four and eight, with a near-significant reduction observed at week 16, the company said, adding that statistically significant results were also observed in several secondary endpoints, including reductions in controlled attenuation parameter and hemoglobin A1C.The drug also demonstrated a strong safety profile, with mostly mild adverse events and no drug-related serious adverse events. MetaVia said that out of 109 randomi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2492185601","title":"BRIEF-Metavia Announces Positive Top-Line Results From Its Phase 2A Clinical Trial Of Da-1241 In Patients With Presumed MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185601","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492185601?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:36","pubTimestamp":1734528998,"startTime":"0","endTime":"0","summary":"Dec 18  - MetaVia Inc   :   * METAVIA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE 2A CLINICAL TRIAL OF DA-1241 IN PATIENTS WITH PRESUMED MASH   * DA-1241 VERY WELL TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS   * DA-1241 SHOWS SIGNIFICANT REDUCTION IN ALT LEVELS AT WEEKS 4 AND 8   * DA-1241 100MG SHOWS SIGNIFICANT IMPROVEMENTS IN CAP SCORE AT WEEK 16   * DA-1241 100MG SHOWS SIGNIFICANT REDUCTIONS IN HBA1C AT WEEK 16   * EXPECTS END OF PHASE 2 MEETING WITH FDA IN FIRST HALF OF 2025Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Metavia Announces Positive Top-Line Results From Its Phase 2A Clinical Trial Of Da-1241 In Patients With Presumed MASH","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2492700188","title":"Metavia Inc - Da-1241 Shows Significant Reduction in Alt Levels at Weeks 4 and 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2492700188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492700188?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA5KYHRG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2492188727","title":"Metavia Inc - Expects End of Phase 2 Meeting With FDA in First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188727?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA5KYHRG:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2492188722","title":"Metavia Inc - Da-1241 Very Well Tolerated With No Drug-Related Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188722?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA5KYHRG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2492188707","title":"Metavia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of Da-1241 in Patients With Presumed Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188707?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA5KYHRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2492183515","title":"MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2492183515","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492183515?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526860,"startTime":"0","endTime":"0","summary":"DA-1241 Demonstrated Direct Hepatic Action in Addition to Its Glucose Lowering Effect. Patients Treated with DA-1241 100mg Achieved Statistically Significant Reduction in ALT Levels at Weeks 4 and 8, and a Near Statistically Significant Reduction at Week 16. DA-1241 100mg Demonstrated Statistically Significant Improvements in CAP Score at Week 16. Awaiting Data on Other Exploratory Endpoints Including MRI-PDFF. Additional Findings to be Submitted for Upcoming Scientific Conferences. * Confidence interval excludes 0, suggesting a statistically meaningful difference. p < 0.05 vs. placebo. Proportion of Subjects with Normalized ALT <30 IU/L at Week 16. LS Mean CAP, VCTE, FAST score Changes from Baseline at Week 16","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-130100214.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-130100214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FAST","BK4104","ALT","BK4599","IE00BFXG0V08.USD","LU1878469433.USD","BK4567","GGT","MTVA","OXM","IE00BYQQ9H92.USD","BK4585","BK4588","BK4139","IE00B5TLWC47.USD","AST","BK4202"],"gpt_icon":0},{"id":"2488923448","title":"MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…","url":"https://stock-news.laohu8.com/highlight/detail?id=2488923448","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488923448?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:33","pubTimestamp":1733225580,"startTime":"0","endTime":"0","summary":"On November 18, 2024, NeuroBo Pharmaceuticals, Inc.  announced a strategic realignment ahead of upcoming clinical milestones along with a corporate name change to MetaVia Inc. . The change went into effect on November 29, 2024. We are republishing the latest research report under the MTVA ticker.MetaVia Inc. is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis . DA-1241 is a novel chemical entity that selectively activates GPR119, stimulates the secretion of insulin and incretin hormones such as glucagon-like peptide-1 , reduces plasma glucose levels without causing hypoglycemia, and lowers plasma lipid levels of both triglycerides and cholesterol.MAD Part 2 Results from Phase 1 Trial of DA-1726 Expected in 1Q25. The multiple ascending dose  Part 2 of the trial is ongoing, with the first patient enrolled in June 2024. A total of 36 individuals are expected to be enrolled in Part 2 of the trial in a 6:3 ratio across four dosing cohorts. Each particip","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6BnuZucQR4TI36e.yZdpVQ--~B/aD04NTY7dz0xMzc0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/daa58845a8f57cfe3cbb544b5bfe2eda","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6BnuZucQR4TI36e.yZdpVQ--~B/aD04NTY7dz0xMzc0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/daa58845a8f57cfe3cbb544b5bfe2eda"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mtva-neurobo-becomes-metavia-topline-113300772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","LU1878469433.USD","MTVA","BK4139","ALT","BK4599","PK","BK4218"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"date":"2025-03-20","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742457600000,"name":null,"time":"Pre-Market","dateTimestamp":1742443200000,"actualEps":null},{"market":"US","date":"2024-11-07","symbol":"MTVA","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.55},{"market":"US","date":"2024-08-14","symbol":"MTVA","fiscalQuarterEnding":"2024/06","expectedEps":-1.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-1.85},{"market":"US","date":"2024-05-09","symbol":"MTVA","fiscalQuarterEnding":"2024/03","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-1.32},{"date":"2024-03-28","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711612800000,"name":null,"time":"Pre-Market","dateTimestamp":1711598400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2025-04-30","current":-0.244696,"percent":0.960396,"low":-0.807761,"twenty":-0.629432,"median":-0.511064,"eighty":-0.458331,"high":-0.229797,"avg":-0.528953,"sd":0.131591,"marketCap":6751663},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270},{"date":"2025-04-25","current":-0.266622,"twenty":-0.631917,"median":-0.512617,"eighty":-0.463425,"marketCap":7356638},{"date":"2025-04-30","current":-0.244696,"twenty":-0.629432,"median":-0.511064,"eighty":-0.458331,"marketCap":6751663}],"updateTime":1746151970051}}}